Canada Markets close in 2 hrs 19 mins

ProMIS Neurosciences, Inc. (PMN.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
7.55-0.05 (-0.66%)
As of 11:36AM EDT. Market open.
Full screen
Previous Close7.60
Open7.60
Bid7.60 x 0
Ask7.74 x 0
Day's Range7.55 - 7.60
52 Week Range6.00 - 13.80
Volume530
Avg. Volume5,323
Market Cap3.26B
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results

    TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 15, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended June 30, 2022. “Q2 was another quarter of strong pro

  • GlobeNewswire

    ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

    Poster presentation of study highlighting oligomer selectivity of PMN310 compared to that of other amyloid-beta-directed antibodiesTORONTO, Ontario and CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, today announced details of its poster pr

  • GlobeNewswire

    ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference

    Poster presentation of study comparing oligomer selectivity of PMN310 to that of other amyloid-beta-directed antibodiesTORONTO, Ontario and CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced it will give a poster presentation